This review provides an in-depth analysis of HER2 (human epidermal growth factor receptor 2) in cancer biology and therapeutics. HER2 is a transmembrane glycoprotein receptor of the EGFR family that plays a critical role in cell proliferation, survival, and differentiation. Aberrant HER2 signaling is implicated in various cancers, particularly breast and gastric cancers, where HER2 overexpression or amplification is associated with aggressive tumor behavior and poor prognosis. HER2-activating mutations contribute to accelerated tumorigenesis and metastasis. The review discusses HER2 biology, signaling pathways, mechanisms of dysregulation, and diagnostic approaches, as well as therapeutic strategies targeting HER2 in cancer. HER2 signaling pathways are critical for cellular function, particularly in cell growth, survival, and differentiation. HER2 can form homodimers or heterodimers with other EGFR family members, with HER2/HER3 heterodimers being particularly potent in activating downstream signaling pathways such as PI3K/AKT and MAPK. HER2 signaling can crosstalk with other pathways, including Akt, Ras, ERK, JNK, Wnt/β-catenin, and NF-κB, influencing cellular responses such as apoptosis, proliferation, and inflammation. HER2 also interacts with hormone receptor pathways, such as estrogen receptor (ER) and progesterone receptor (PR), which can influence therapeutic response. HER2-based therapeutic strategies include monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs). These therapies have significantly improved outcomes for HER2-positive breast cancer patients. However, resistance to HER2-targeted therapies remains a challenge, particularly in HER2-mutated cancers. Understanding the molecular mechanisms of HER2 dysregulation and resistance is essential for developing effective targeted therapies. HER2 status is an essential prognostic and predictive marker in breast cancer. HER2-positive breast cancer tends to have a poorer prognosis than HER2-negative breast cancer, but targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer. HER2 is also implicated in metastasis, with HER2 overexpression, amplification, and mutations associated with increased metastatic potential and poor prognosis in various cancers. HER2 plays a role in immune regulation and response, with HER2-positive tumors often exhibiting increased immune infiltration. HER2-targeted therapies can enhance immune recognition of HER2-positive tumor cells, but immune evasion and resistance remain challenges. Combination therapies targeting HER2 and immune checkpoints are being investigated to overcome resistance and enhance antitumor immune responses. The review highlights the importance of HER2 in cancer biology and the need for continued research into HER2-targeted therapies, including next-generation ADCs, bispecific antibodies, and combination therapies. Understanding the complex interactions between HER2 and other signaling pathways is crucial for developing effective therapeutic strategies. The future of HER2 research lies in an integrated approach that combines advanced therapeutic strategies, precision medicine,This review provides an in-depth analysis of HER2 (human epidermal growth factor receptor 2) in cancer biology and therapeutics. HER2 is a transmembrane glycoprotein receptor of the EGFR family that plays a critical role in cell proliferation, survival, and differentiation. Aberrant HER2 signaling is implicated in various cancers, particularly breast and gastric cancers, where HER2 overexpression or amplification is associated with aggressive tumor behavior and poor prognosis. HER2-activating mutations contribute to accelerated tumorigenesis and metastasis. The review discusses HER2 biology, signaling pathways, mechanisms of dysregulation, and diagnostic approaches, as well as therapeutic strategies targeting HER2 in cancer. HER2 signaling pathways are critical for cellular function, particularly in cell growth, survival, and differentiation. HER2 can form homodimers or heterodimers with other EGFR family members, with HER2/HER3 heterodimers being particularly potent in activating downstream signaling pathways such as PI3K/AKT and MAPK. HER2 signaling can crosstalk with other pathways, including Akt, Ras, ERK, JNK, Wnt/β-catenin, and NF-κB, influencing cellular responses such as apoptosis, proliferation, and inflammation. HER2 also interacts with hormone receptor pathways, such as estrogen receptor (ER) and progesterone receptor (PR), which can influence therapeutic response. HER2-based therapeutic strategies include monoclonal antibodies, small-molecule inhibitors, and antibody-drug conjugates (ADCs). These therapies have significantly improved outcomes for HER2-positive breast cancer patients. However, resistance to HER2-targeted therapies remains a challenge, particularly in HER2-mutated cancers. Understanding the molecular mechanisms of HER2 dysregulation and resistance is essential for developing effective targeted therapies. HER2 status is an essential prognostic and predictive marker in breast cancer. HER2-positive breast cancer tends to have a poorer prognosis than HER2-negative breast cancer, but targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer. HER2 is also implicated in metastasis, with HER2 overexpression, amplification, and mutations associated with increased metastatic potential and poor prognosis in various cancers. HER2 plays a role in immune regulation and response, with HER2-positive tumors often exhibiting increased immune infiltration. HER2-targeted therapies can enhance immune recognition of HER2-positive tumor cells, but immune evasion and resistance remain challenges. Combination therapies targeting HER2 and immune checkpoints are being investigated to overcome resistance and enhance antitumor immune responses. The review highlights the importance of HER2 in cancer biology and the need for continued research into HER2-targeted therapies, including next-generation ADCs, bispecific antibodies, and combination therapies. Understanding the complex interactions between HER2 and other signaling pathways is crucial for developing effective therapeutic strategies. The future of HER2 research lies in an integrated approach that combines advanced therapeutic strategies, precision medicine,